BRIEF — Lenvima commercialization collaboration gets underway in Japan

Eisai and Merck & Co have started joint medical and marketing activities for the tyrosine kinase inhibitor Lenvima (lenvatinib mesylate) in Japan.

The partners agreed a strategic collaboration for the worldwide co-development and co-commercialization of the multi-indication cancer drug in March of this year.

They will work together in Japan firstly by providing information on Lenvima in hepatocellular carcinoma.